SINGAPOREMay 21, 2026 /PRNewswire/ — KBP Biosciences Pte. Ltd. (“Company“ or “KBP“) today issued a statement in response to the ruling by the Singapore Court of Appeal, which upheld the interim injunction against the Company and its founder, Dr. Huang Zhenhua (“Dr. Huang“), pending the final resolution of arbitration proceedings with Novo Nordisk A/S (“Novo Nordisk“). The Company expressed disappointment with the decision to uphold the injunction, but the appellate ruling very clearly indicated that the substantive issues raised by Novo Nordisk must be determined by the arbitral tribunal. Currently, arbitration proceedings initiated by both parties are ongoing.
1. Court of Appeal Did Not Find Fraud or Dishonesty
Section 12A of Singapore’s International Arbitration Act authorizes Singapore courts to issue interim injunctions during arbitration to preserve the status quo. This does not involve a review of the substantive dispute.
The Court of Appeal explicitly stated that the Singapore court did not make any finding of fraud or dishonesty against the Company or Dr. Huang, and expressed in unequivocal terms: “The judge did not make a finding of dishonesty: that is a matter for the (arbitral) decision-maker hearing the case to decide“.
The Court of Appeal further noted: “The merits of the various claims raised by Novo and all defenses of the appellants are ultimately to be finally determined in the arbitration, independently of and without being influenced by the (Singapore) judge’s finding of a ‘serious question to be tried‘“.
Therefore, Novo Nordisk‘s fraud allegations have not been substantiated. The Company is confident that these fraud allegations will be robustly dismissed in the final ruling of the arbitral tribunal.
2. Court of Appeal Confirms Novo Nordisk Received and Could Access KBP‘s Raw Data
The Company noted that the Court of Appeal confirmed Novo Nordisk had obtained documents from KBP, including raw data:
“KBP uploaded to the data room a series of PDF files, which contained vital signs data for each patient participating in the Phase 2 clinical trial, i.e., the ‘Vital Signs Data Listing‘.
KBP also uploaded a set of files named ‘CTA Package’, which had previously been submitted to China’s National Medical Products Administration, and which contained Phase 2 clinical trial data.
Notably, these files enabled Novo to access patient-level data, including the clinical trial site for each patient and their systolic blood pressure (“SBP”).“
The Company maintains its position that it provided Novo Nordisk with all material information necessary to make an informed decision regarding the acquisition of Ocedurenone. Any allegations of misrepresentation or fraud against the Company or Dr. Huang are entirely unfounded.
3. Novo Nordisk‘s Decision to Halt Development
The Company further reiterates its position: Novo Nordisk‘s decision to halt the development of Ocedurenone was wrong, and it will demonstrate this to the arbitral tribunal.
Dr. Huang stated: “We, along with multiple independent industry experts, believe that Novo ‘s decision to terminate the Phase 3 clinical trial and halt the Ocedurenone program was wrong and without any valid justification. This hasty termination not only contradicts established scientific principles and sound clinical judgment, but also has prevented a drug that had the potential to gain regulatory approval and benefit a broad patient population from reaching the market, severely harming patients’ potential benefits. We deeply regret and lament this outcome.“
The Company is currently unable to comment further on the ongoing arbitration proceedings, but the Company and Dr. Huang will steadfastly maintain their positions and actively assert and defend all rights in the arbitration.
About KBP Biosciences
KBP is a global, clinical-stage biotechnology company headquartered in Singapore, focused on the discovery, development, and commercialization of small molecule therapeutics for serious cardiorenal diseases and infectious diseases with significant unmet medical needs.